(erythromycin 3%-benzoyl peroxide 5% topical gel)
For Dermatological Use Only – Not for Ophthalmic Use
Benzamycin® Pak contains erythromycin [(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-dideoxy-3-C-
xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione]. Erythromycin is a macrolide antibiotic produced from a strain of Saccharopolyspora erythraea (formerly Streptomyces erythreus). It is a base and readily forms salts with acids.
Benzamycin ® Pak is indicated for the topical treatment of acne vulgaris.
Media Articles Related to Benzamycin (Erythromycin / Benzoyl Peroxide Topical)
Researchers use the latest in nanotechnology and transdermal drug delivery to take on an old problem: Acne
Source: MRI / PET / Ultrasound News From Medical News Today [2015.03.24]
Acne, a scourge of adolescence, may be about to meet its ultra high-tech match.
Many Acne Patients Don't Take Their Meds, Survey Shows
Source: MedicineNet Acne Specialty [2015.03.23]
Title: Many Acne Patients Don't Take Their Meds, Survey Shows
Category: Health News
Created: 3/20/2015 12:00:00 AM
Last Editorial Review: 3/23/2015 12:00:00 AM
Acne patients: 'substantial proportion' fail to collect prescribed treatment
Source: Compliance News From Medical News Today [2015.03.22]
Dermatologist-prescribed treatments are being left on pharmacy shelves by up to a quarter of people with acne, according to a new study.
Better Contraceptive Knowledge Can Aid in Safe Use of Acne Drug: Study
Source: MedicineNet Birth Defects Specialty [2015.02.05]
Title: Better Contraceptive Knowledge Can Aid in Safe Use of Acne Drug: Study
Category: Health News
Created: 2/4/2015 12:00:00 AM
Last Editorial Review: 2/5/2015 12:00:00 AM
Source: MedicineNet Boils Specialty [2014.10.17]
Title: Acne (Pimples)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/17/2014 12:00:00 AM
Clinical Trials Related to Benzamycin (Erythromycin / Benzoyl Peroxide Topical)
Patients Response to Early Switch To Oral:Osteomyelitis Study [Not yet recruiting]
Based on the current literature, investigators hypothesize that patients with osteomyelitis
who are treated with the standard approach of intravenous antibiotics for the full duration
of therapy will have the same clinical outcomes as patients treated with the experimental
approach of intravenous antibiotics with early switch to oral antibiotics.
The primary objective of this study is to compare patients with osteomyelitis treated with
the standard approach of intravenous antibiotics for the full duration of therapy versus
patients treated with intravenous antibiotics with an early switch to oral antibiotics in
relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy.
Secondary objectives of the study include the evaluation of adverse events related to the
use of antibiotics as well as the cost of care evaluated from the hospital perspective.